Back to Search Start Over

Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Authors :
Paz-Ares, L.
Chen, Y.
Reinmuth, N.
Hotta, K.
Trukhin, D.
Statsenko, G.
Goldman, J. W.
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

[No Abstract Available] AstraZenecaAstraZeneca AstraZeneca.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.od.....10033..8ab521b0e7a7789f13691282d4776592

Tools

Authors Abstract Subjects Details